Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CTR9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CTR9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CTR9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CTR9_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CTR9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017015 | Liver | Cirrhotic | in utero embryonic development | 134/4634 | 367/18723 | 2.78e-07 | 6.86e-06 | 134 |
GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
GO:003009912 | Liver | Cirrhotic | myeloid cell differentiation | 135/4634 | 381/18723 | 1.69e-06 | 3.22e-05 | 135 |
GO:00506863 | Liver | Cirrhotic | negative regulation of mRNA processing | 19/4634 | 29/18723 | 4.10e-06 | 6.90e-05 | 19 |
GO:001605511 | Liver | Cirrhotic | Wnt signaling pathway | 150/4634 | 444/18723 | 9.75e-06 | 1.42e-04 | 150 |
GO:190331212 | Liver | Cirrhotic | negative regulation of mRNA metabolic process | 42/4634 | 92/18723 | 9.99e-06 | 1.45e-04 | 42 |
GO:019873811 | Liver | Cirrhotic | cell-cell signaling by wnt | 150/4634 | 446/18723 | 1.28e-05 | 1.80e-04 | 150 |
GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
GO:003105611 | Liver | Cirrhotic | regulation of histone modification | 59/4634 | 152/18723 | 8.28e-05 | 9.02e-04 | 59 |
GO:19033222 | Liver | Cirrhotic | positive regulation of protein modification by small protein conjugation or removal | 52/4634 | 138/18723 | 4.91e-04 | 3.94e-03 | 52 |
GO:00324966 | Liver | Cirrhotic | response to lipopolysaccharide | 111/4634 | 343/18723 | 8.15e-04 | 5.95e-03 | 111 |
GO:001982711 | Liver | Cirrhotic | stem cell population maintenance | 48/4634 | 131/18723 | 1.58e-03 | 1.03e-02 | 48 |
GO:0031398 | Liver | Cirrhotic | positive regulation of protein ubiquitination | 44/4634 | 119/18723 | 1.98e-03 | 1.23e-02 | 44 |
GO:001657411 | Liver | Cirrhotic | histone ubiquitination | 21/4634 | 47/18723 | 2.24e-03 | 1.36e-02 | 21 |
GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
GO:009872711 | Liver | Cirrhotic | maintenance of cell number | 48/4634 | 134/18723 | 2.70e-03 | 1.58e-02 | 48 |
GO:00022376 | Liver | Cirrhotic | response to molecule of bacterial origin | 113/4634 | 363/18723 | 3.23e-03 | 1.81e-02 | 113 |
GO:0031440 | Liver | Cirrhotic | regulation of mRNA 3'-end processing | 14/4634 | 28/18723 | 3.40e-03 | 1.89e-02 | 14 |
GO:0031123 | Liver | Cirrhotic | RNA 3'-end processing | 42/4634 | 116/18723 | 3.85e-03 | 2.10e-02 | 42 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTR9 | SNV | Missense_Mutation | | c.2140C>G | p.His714Asp | p.H714D | Q6PD62 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
CTR9 | SNV | Missense_Mutation | | c.493N>A | p.Ala165Thr | p.A165T | Q6PD62 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD |
CTR9 | SNV | Missense_Mutation | | c.2311N>A | p.Asp771Asn | p.D771N | Q6PD62 | protein_coding | tolerated(0.15) | benign(0.012) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CTR9 | SNV | Missense_Mutation | rs777109871 | c.1555N>G | p.Leu519Val | p.L519V | Q6PD62 | protein_coding | deleterious(0.03) | benign(0.376) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTR9 | SNV | Missense_Mutation | | c.2239N>A | p.Ala747Thr | p.A747T | Q6PD62 | protein_coding | deleterious(0.01) | benign(0.122) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CTR9 | insertion | Frame_Shift_Ins | novel | c.783_784insACCTTTG | p.Tyr262ThrfsTer6 | p.Y262Tfs*6 | Q6PD62 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
CTR9 | insertion | Nonsense_Mutation | novel | c.1373_1374insATAAAAGAGAT | p.Ala459Ter | p.A459* | Q6PD62 | protein_coding | | | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
CTR9 | SNV | Missense_Mutation | rs760130762 | c.1427N>T | p.Ala476Val | p.A476V | Q6PD62 | protein_coding | tolerated(0.28) | benign(0.083) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CTR9 | SNV | Missense_Mutation | | c.2732N>G | p.Ser911Cys | p.S911C | Q6PD62 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CTR9 | SNV | Missense_Mutation | novel | c.2680G>A | p.Glu894Lys | p.E894K | Q6PD62 | protein_coding | tolerated(0.86) | benign(0.05) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |